MaxCyte, Inc. License with Intima Bioscience (2329A)
February 01 2022 - 1:59AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 2329A
MaxCyte, Inc.
01 February 2022
MaxCyte Signs Strategic Platform License with Intima
Bioscience
to Advance Tumor Infiltrating Lymphocytes Programs
Intima Bioscience to use MaxCyte's Flow Electroporation (R)
technology and ExPERT(TM) platform to accelerate the development of
its solid tumor cell-therapy candidates
New yorK City, NY and GAITHERSBURG, MD, Feb. 1, 2022 - MaxCyte,
Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of
enabling platform technologies for ex-vivo cell engineering, today
announces the signing of a strategic platform license (SPL) with
Intima Bioscience, Inc., a clinical stage biotechnology company
developing genetically engineered cell therapies for solid tumor
cancer. Intima joins a group of 15 other leading cell therapy
companies who have partnered with MaxCyte.
Under the terms of the agreement, Intima obtains non-exclusive
clinical and commercial rights to use MaxCyte's Flow
Electroporation(R) technology and ExPERT(TM) platform. In return,
MaxCyte is entitled to receive platform licensing fees and
program-related milestone payments.
Intima is currently running a Phase 1/2 clinical study
(NCT04426669) of its lead checkpoint cell therapy candidate, which
targets the immune checkpoint CISH in patients with
gastrointestinal and colon cancers.
"As we advance our innovative eTIL CISH knock out programs, we
are preparing for the future by securing access to MaxCyte's
industry leading cellular engineering technology," said Alessandro
Riva, M.D., Intima CEO.
Doug Doerfler, President and CEO of MaxCyte , said: "We are
proud to be working with Intima, a cell therapy leader leveraging
the unique power of genetically engineered tumor infiltrating
lymphocytes (eTIL). This relationship represents an important
achievement for MaxCyte as it expands the use of our
next-generation technology platform to support engineering in
additional novel cell types."
MaxCyte's ExPERT(TM) instrument portfolio is the next generation
of leading, clinically-validated, electroporation technology for
complex and scalable cell engineering. By delivering high
transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT(TM) platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. Intima Bioscience is MaxCyte's 16th SPL
which generate pre-commercial milestone revenue and the vast
majority of which include post-commercial revenue.
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation(R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM)
GTx(TM)and VLx(TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
About Intima Bioscience
Intima Bioscience is a company advancing checkpoint cell
therapy, an approach that combines the use of patients' own immune
cells with immune checkpoint targeting, in solid tumors with
curative intent. Intima is currently running a Phase 1/2 clinical
study of its checkpoint cell therapy, which targets the immune
checkpoint CISH in patients with gastrointestinal and colon
cancers.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSDAEEFEESELF
(END) Dow Jones Newswires
February 01, 2022 01:59 ET (06:59 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024